Strategic Merck Synergy Leverage Merck's global footprint and sales force now that Acceleron is a Merck subsidiary to accelerate adoption of sotatercept in PAH across markets, with potential cross-sell opportunities to Merck's cardiovascular and specialty portfolios.

PAH Expansion Sotatercept represents a novel mechanism for PAH; explore additional indications or combination regimens in ongoing or new trials to broaden the addressable market, supported by Merck's resources.

Global Market Access Utilize Merck's payer networks and access capabilities to secure faster reimbursement and pricing discussions for sotatercept, shortening time-to-market and increasing physician adoption.

Pipeline Monetization With Merck ownership, Acceleron's assets and related opportunities can be advanced through licensing, co-development, or negotiations with external partners to monetize the pipeline more efficiently.

Financial Backing The acquisition provides strong financial backing and resilience, enabling aggressive investments in late-stage trials, commercialization, and geographic expansion to grow sales faster.